上海医药(02607)：2019年A股股票期权激励计划首次授予股票期权第三个行权期可行权股票期权数量697.68万份

智通财经2025-03-04

智通财经APP讯，上海医药(02607)发布公告，该公司2019年A股股票期权激励计划(“本次股权激励计划”)首次授予股票期权第三个行权期可行权股票期权数量697.68万份，行权期自2024年2月14日起至2025年2月13日止，行权方式为自主行权。截至2025年2月13日，激励对象累计行权并完成股份过户登记482.89万股，占当期可行权股票期权总量的69.21%。预留股票期权第二个行权期可行权...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2516626032?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-03-04 18:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2516626032","market":"sh","top_or_hot":-1,"title":"上海医药(02607)：2019年A股股票期权激励计划首次授予股票期权第三个行权期可行权股票期权数量697.68万份","media":"智通财经","content":"<div>\n<p>智通财经APP讯，上海医药(02607)发布公告，该公司2019年A股股票期权激励计划(“本次股权激励计划”)首次授予股票期权第三个行权期可行权股票期权数量697.68万份，行权期自2024年2月14日起至2025年2月13日止，行权方式为自主行权。截至2025年2月13日，激励对象累计行权并完成股份过户登记482.89万股，占当期可行权股票期权总量的69.21%。预留股票期权第二个行权期可行权...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1257578.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>上海医药(02607)：2019年A股股票期权激励计划首次授予股票期权第三个行权期可行权股票期权数量697.68万份</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n上海医药(02607)：2019年A股股票期权激励计划首次授予股票期权第三个行权期可行权股票期权数量697.68万份\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-04 18:11 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1257578.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，上海医药(02607)发布公告，该公司2019年A股股票期权激励计划(“本次股权激励计划”)首次授予股票期权第三个行权期可行权股票期权数量697.68万份，行权期自2024年2月14日起至2025年2月13日止，行权方式为自主行权。截至2025年2月13日，激励对象累计行权并完成股份过户登记482.89万股，占当期可行权股票期权总量的69.21%。预留股票期权第二个行权期可行权...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1257578.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"399300","symbol_name":"沪深300","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1257578.html","article_id":"2516626032","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2516626032","pubTimestamp":1741083074,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，上海医药 发布公告，该公司2019年A股股票期权激励计划首次授予股票期权第三个行权期可行权股票期权数量697.68万份，行权期自2024年2月14日起至2025年2月13日止，行权方式为自主行权。预留股票期权第二个行权期可行权股票期权数量75.57万份，行权期自2024年2月8日起至2025年2月7日止，行权方式为自主行权。截至2025年2月7日，激励对象累计行权并完成股份过户登记23.19万股，占当期可行权股票期权数量的30.68%。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159982":"中证500","399300":"沪深300","601607":"上海医药","BK0187":"一线龙头","BK0184":"上海国资改革","BK0097":"医药电商","BK0099":"上海本地重组","BK0028":"国家队","BK1197":"保健护理产品经销商","BK0020":"浦东新区","BK0209":"零售","BK0183":"MSCI概念","02607":"上海医药","BK0175":"白马股","BK0188":"融资融券","BK0012":"证金概念","BK0196":"行业龙头"},"translate_title":"Shanghai Pharmaceuticals (02607): The 2019 A-share stock option incentive plan granted stock options for the first time. The number of exercisable stock options during the third exercise period is 6.9768 million","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159982":1,"399300":1,"601607":1,"02607":1},"content_text":"智通财经APP讯，上海医药(02607)发布公告，该公司2019年A股股票期权激励计划(“本次股权激励计划”)首次授予股票期权第三个行权期可行权股票期权数量697.68万份，行权期自2024年2月14日起至2025年2月13日止，行权方式为自主行权。截至2025年2月13日，激励对象累计行权并完成股份过户登记482.89万股，占当期可行权股票期权总量的69.21%。预留股票期权第二个行权期可行权股票期权数量75.57万份，行权期自2024年2月8日起至2025年2月7日止，行权方式为自主行权。截至2025年2月7日，激励对象累计行权并完成股份过户登记23.19万股，占当期可行权股票期权数量的30.68%。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2516626032","isCrawlerRequest":true}